Related Experiment Videos
Innate Immune Cells' Contribution to Systemic Lupus Erythematosus
Andrés A Herrada1, Noelia Escobedo1, Mirentxu Iruretagoyena2
1Lymphatic and Inflammation Research Laboratory, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile.
Frontiers in Immunology
|May 1, 2019
Summary
Systemic lupus erythematosus (SLE) involves autoantibodies and T cells, but innate immunity is now recognized as crucial. This review highlights innate immune cells and pathways in SLE pathogenesis and potential new therapies targeting these components.
Area of Science:
- Immunology
- Autoimmunity
- Rheumatology
Background:
- Systemic lupus erythematosus (SLE) is a chronic autoimmune disease.
- Characterized by autoantibodies, immune complex deposition, and multi-organ damage.
- B cells and T cells have established roles, but innate immunity's involvement is increasingly recognized.
Purpose of the Study:
- To review recent evidence on the role of innate immune cells and pathways in SLE pathogenesis.
- To discuss emerging therapeutic targets within the innate immune system for SLE treatment.
Main Methods:
- Literature review of recent research on innate immunity in SLE.
- Analysis of studies investigating innate immune cell subsets and mediators.
- Examination of therapeutic strategies targeting innate immune components.
Main Results:
- Innate immune cells and molecules play a significant role in promoting and potentiating SLE.
- Specific innate immune pathways are implicated in the disease's pathology.
- Several innate immune targets show promise for novel SLE therapies.
Conclusions:
- Innate immunity is a critical factor in SLE pathogenesis.
- Targeting innate immune components offers a promising avenue for developing new SLE treatments.